Pierre Gerard Cassigneul
Director/Board Member chez Enterome SA
Profil
Pierre Gerard Claude Cassigneul is an Independent Director at Enterome SA. He previously served as the President & Chief Executive Officer at CareDx, Inc. from 2003 to 2012.
Additionally, he was the Chief Executive Officer at Predictive Biosciences, Inc. in 2013.
Mr. Cassigneul also held positions as the President & Chief Executive Officer at NMS Labs and as a Director at The Bay Area Bioscience Association and Microbiome Diagnostics Partners SA. He worked as a Principal at Abbott Laboratories and Bayer Corp.
He was also an Operating Partner at Stone Bridge Management LLC from 2002 to 2003.
Mr. Cassigneul started his career as a Vice President-Diabetes Management at Becton, Dickinson & Co. from 2001 to 2002.
He obtained his undergraduate degree from Ecole Supérieure de Commerce de Reims.
Postes actifs de Pierre Gerard Cassigneul
| Sociétés | Poste | Début |
|---|---|---|
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Director/Board Member | 01/01/2013 |
Anciens postes connus de Pierre Gerard Cassigneul
| Sociétés | Poste | Fin |
|---|---|---|
| Stone Bridge Management LLC | Corporate Officer/Principal | 01/08/2003 |
| BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | 01/07/2002 |
Microbiome Diagnostics Partners SA
 Microbiome Diagnostics Partners SA BiotechnologyHealth Technology Microbiome Diagnostics Partners SA develops and commercializes microbiome-based diagnostics. The company was founded on August 8, 2017 and is headquartered in Epalinges, Switzerland. | Director/Board Member | - |
NMS Labs
 NMS Labs Miscellaneous Commercial ServicesCommercial Services NMS Labs provides professional, state-of-the-art laboratory diagnostic services to clinicians, members of the criminal and civil justice communities, and those researching and developing new therapeutics. It offers forensic services, clinical services and research services. The company was founded by Fredric Rieders in 1970 and is headquartered in Willow Grove, PA. | Chief Executive Officer | - |
Predictive Biosciences, Inc.
 Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Chief Executive Officer | - |
Formation de Pierre Gerard Cassigneul
| Ecole Supérieure de Commerce de Reims | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| BECTON, DICKINSON AND COMPANY | Health Technology |
| CAREDX, INC | Health Technology |
| Entreprise privées | 7 |
|---|---|
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Health Technology |
| The Bay Area Bioscience Association | Health Technology |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Health Services |
| Stone Bridge Management LLC | |
NMS Labs
NMS Labs Miscellaneous Commercial ServicesCommercial Services NMS Labs provides professional, state-of-the-art laboratory diagnostic services to clinicians, members of the criminal and civil justice communities, and those researching and developing new therapeutics. It offers forensic services, clinical services and research services. The company was founded by Fredric Rieders in 1970 and is headquartered in Willow Grove, PA. | Commercial Services |
Enterome SA
Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
Microbiome Diagnostics Partners SA
Microbiome Diagnostics Partners SA BiotechnologyHealth Technology Microbiome Diagnostics Partners SA develops and commercializes microbiome-based diagnostics. The company was founded on August 8, 2017 and is headquartered in Epalinges, Switzerland. | Health Technology |
